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Background: The rise of the internet and related technologies has significant implications for the treatment of
complex health problems, including the combination of depression and alcohol/other drug (AOD) misuse. To
date, no research exists to test the real world uptake of internet and computer-delivered treatment programs in
clinical practice. This study is important, as it is the first to examine the adoption of the SHADE treatment
program, a DVD-based psychological treatment for depression and AOD use comorbidity, by clinicians working in
a publicly-funded AOD clinical service. The study protocol that follows describes the methodology of this
dissemination trial.
Methods/design: 19 clinicians within an AOD service on the Central Coast of New South Wales, Australia, will
be recruited to the trial. Consenting clinicians will participate in a baseline focus group discussion designed to
explore their experiences and perceived barriers to adopting innovation in their clinical practice. Computer
comfort and openness to innovation will also be assessed. Throughout the trial, current, new and wait-list
clients will be referred to the research program via the clinical service, which will involve clients completing a
baseline and 15-week follow-up clinical assessment with independent research assistants, comprising a range of
mental health and AOD measures. Clinicians will also complete session checklists following each clinical session
with a client, outlining the extent to which the SHADE computer program was used. Therapeutic alliance will
be measured at intake and discharge from both the clinician and client perspectives.
Discussion: This study will provide comprehensive data on the factors associated with the adoption of an
innovative, computer-delivered evidence-based treatment program, SHADE, by clinicians working in an AOD
service. The results will contribute to the development of a model of dissemination of SHADE, which could be
applied to a range of technological innovations.
Clinical trials registry: Australian Clinical Trial Registration Number: ACTRN12611000382976.* Correspondence: f.kaylambkin@unsw.edu.au
1National Drug and Alcohol Research Centre, University of New South Wales,
Sydney, Australia
2Centre for Brain and Mental Health Research (CBMHR), University of
Newcastle, Newcastle, Australia
Full list of author information is available at the end of the article
© 2012 Kay-Lambkin et al.; Licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Kay-Lambkin et al. BMC Psychiatry 2012, 12:77 Page 2 of 7
http://www.biomedcentral.com/1471-244X/12/77Background
Mounting pressure is exerted on the health system by
the increasing prevalence of depression and alcohol/
other drug (AOD) misuse. These disorders are ranked 3
and 17 in contribution to the global disease burden, with
depression elevated to 1st place and alcohol abuse use to
5th among middle-high income countries such as Aus-
tralia [1]. Efficacious treatments have been tested with
success for both depression [2] and AOD disorders [3],
suggesting that this burden can be reduced.
Despite this, the gap between need for and receipt of
these treatments is large, particularly for counselling [4],
which is often preferred over pharmacotherapy [5]. For
example, in the US, 2.1 million people with a 12-month
mental disorder did not use services for mental health
problems but perceived they had an unmet need [6]. Of
these, the highest unmet need was for counselling [6].
Comorbidity, or the co-occurrence of two or more disor-
ders, is the rule rather than the exception in clinical
practice [7], with up to 89% of people with AOD use dis-
orders also experiencing depression [8]. The presence of
comorbid disorders compounds difficulties in treatment
access and provision [9].
Mental health and AOD researchers and clinicians
must respond to these issues, by developing and evaluat-
ing treatment programs that address depression and
AOD use disorders, whilst minimising cost and maxi-
mising efficient use of clinician time and client out-
comes. Available evidence-based treatments provide for
single problems (e.g. depression or alcohol misuse) ra-
ther than the comorbidity with which clients typically
present [7]. Treatments are often high intensity, require
specialist input and training, and are therefore only ac-
cessible to a minority of clients [10]. For these reasons,
many clinicians are not able, or willing, to implement
these interventions in practice.
The increased availability and use of computer/inter-
net-based programs as a supplement to health care is
also a potential solution to well-documented treatment
accessibility problems [11], particularly among people
with depression and AOD use comorbidity. Interactive
and multimedia options offer the potential for higher
levels of engagement than other self-help modalities
[12]. Computers/the internet offer the opportunity for
widespread dissemination of treatments, reaching a large
audience in a cost effective and timely manner [13].
Experts also suggest that the integration of internet/
computer-delivered interventions into practice, will in-
crease adherence to evidence-based treatment protocols,
and increase the number of practitioners who can de-
liver highly specialized psychological treatments [14].
Internet/computerized CBT treatment programs have
established efficacy for a range of mental disorders and
other health conditions [15]. Our previous work hasreported on the efficacy of computerized psychological
treatment for concurrent depression and AOD use dis-
orders [SHADE treatment, 16]. In a recent randomized
controlled clinical trial involving 97 participants, SHADE
computerized treatment was associated with significantly
greater reductions in depression relative to a one-session
treatment, and equivalent reductions in depression to a
face-to-face treatment combining cognitive behavioural
therapy (CBT) and motivation enhancement (ME).
There was a significant advantage of computerized
SHADE for marijuana use over time, with participants
in SHADE reporting twice the reduction in marijuana
use as the face-to-face condition and approximately five
times the reduction as the one-session treatment at 12
month follow-up [16]. Computerized SHADE was also
associated with similar reductions in alcohol use over 12
months as the equivalent face-to-face-delivered combin-
ation CBT/ME program [16].
Whilst it is generally accepted that internet/computer-
delivered CBT programs are efficacious, with some in-
dicating equivalent benefits to face-to-face-delivered
programs, there is very little real world research that
demonstrates the benefits and acceptability of these pro-
grams in practice and service settings [14]. There is
some evidence to suggest that, in the US, only 48% of
primary care patients would consider using internet-
delivered CBT, compared to 91% for traditional face-to-
face therapy [14]. However, other evidence suggests that
clinicians, including psychologists and CBT practi-
tioners, are more open to using these alternatives as sup-
plements to the care they are able to provide [17].
Consequently, the current study was commenced with
the aim of exploring clinician and client uptake, accessi-
bility and response to a computerized CBT/ME treat-
ment for depression and AOD use (SHADE treatment)
within a publicly-funded Drug and Alcohol Clinician
Service in New South Wales, Australia.Methods/design
Study aims
The purpose of this original research is to test the effect-
iveness of the SHADE computerized treatment program,
from both a clinician and client perspective, within the
real world clinical setting. It is hypothesised that clients
exposed to the SHADE program will report superior
reductions in depression and AOD use relative to those
who are not exposed, and that this response may be
moderated by primary drug of concern (e.g. marijuana
vs. other drug use), coercion into treatment and com-
puter comfort. It is also hypothesised that there will be
an association between clinician openness to innovation,
clinician computer comfort and the use of SHADE in
clinical practice.
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This is a real world dissemination trial, conducted within
a publicly-funded Drug and Alcohol Clinical Service
(DACS) on the Central Coast of New South Wales, Aus-
tralia. It forms part of the area’s general health service
for a population of 306,257. The DACS forms part of a
general health service, and provides a range of clinical
interventions to residents within the catchment area
with AOD use problems. Services include counselling,
detoxification (hospital-based and outreach), needle and
syringe programs, pharmacotherapy services, a diversion
program for people with AOD use problems and legal
issues (Magistrates Early Referral Into Treatment,
MERIT), and a specialist service targeting clients with a
primary drug of concern of marijuana. A central intake
service acts as the point of initial contact for access to
DACS, with subsequent referrals made to relevant ser-
vices as appropriate. Client and Clinician participants
will be recruited from the counselling services associated
with the Central Coast DACS. There are three counsel-
ling teams within this service, AOD Counselling,
Marijuana Clinic and MERIT. In a study conducted at
the NSW Central Coast Cannabis Clinic, it was found
that clients on average only attended 2.8 treatment ses-
sions, which is lower than the Drug and Alcohol Coun-
selling Team within the same service which had an
average of 4.5 treatment sessions in 2006 [18]. Clients
attending the MERIT program are mandated to attend
12 sessions of treatment.
Participants – clinicians
Clinicians working within the Counselling, Marijuana
Clinic and MERIT teams will be invited to participate in
the study. At a minimum, these clinicians will have a ter-
tiary education in a counselling-related field, with at
least an undergraduate degree in nursing or psychology.
Participants – clients
All clients, new and ongoing, will be invited to partake
in the study. Participants will be aged 18 years and over
and residing on the Central Coast and surrounding areas
of New South Wales. Participants will consist of indivi-
duals attending counselling with primary presenting
issues related to substance abuse or dependence. No ex-
clusion criteria will be applied to participants (e.g.
comorbid conditions), and it is expected that at least
50% of the clients will be experiencing co-occurring de-
pression or anxiety and many will be poly-drug users. In
2006-7, 2,632 calls were received by the central intake
service for the Area Health Region in which the Central
Coast DACS is located, with 64% of these being referred
to Central Coast DACS. Within the service, 3,329 treat-
ment episodes were commenced, with 73% of clients
completing treatment [19]. The majority of these (61%)were for males, aged 20-39 years (51%), with alcohol
being the most common primary drug of concern (49%).
Study design
This study is designed to observe, and not prescribe, the
use of the SHADE computerized treatment program
within the Central Coast DACS. Ethics approval for the
study has been obtained from several relevant Human
Research Ethics Committees, led by the Northern Syd-
ney Central Coast Human Research Ethics Committee
(08/HARBR/78/79), and including the University of
Newcastle Human Research Ethics Committee (H-2008-
0271), and the Macquarie University Ethics Review
Committee (Human Research, 0806-125M(R)).
Clinicians
At information sessions conducted by the authors, clini-
cians in each team associated with the DACS were intro-
duced to the study and asked to provide consent to
participate. Participation involves five activities:
(1) Completion of a baseline focus group discussion
regarding the use of innovation in clinical practice.
(2) Completion of a baseline questionnaire regarding
their openness to innovation and computer
comfort.
(3) Use of the SHADE treatment program with new
and ongoing clients in whatever manner they
choose, with delivery of the DVD content of the
program either contained within the clinic session
or provided to clients to complete in their own
home in between clinic sessions.
(4) Referral of contact details for new and ongoing
clients to the client-data-collection phase
throughout the study period, regardless of their
exposure to the SHADE treatment program.
(5) Completion of session checklists (see Appendix A)
following every counselling session with new and
ongoing clients, regardless of their exposure to the
SHADE treatment program, and therapeutic
alliance measures at intake and discharge for all
clients.
Clinicians are provided with a half-day tutorial on
the SHADE resource conducted by the research team.
The content of this tutorial includes a discussion of the
results of the previous clinical trials conducted using the
SHADE program, and orientation to the SHADE re-
source. Clinicians split into groups of two and worked
through a different SHADE module on laptops provided
by the research team. At the conclusion of this session,
clinicians presented each module to the group, and dis-
cussed ways in which they felt the module could be inte-
grated into their clinical work at the DACS. Researchers
Table 1 Clinician focus group protocol
(1) What sources do you use to inform your clinical practice (e.g.
journals, workshops, clinical guidelines)?
(2) What influences you in deciding on when to use a particular
strategy, technique, or resource during a session with a client? How
do handouts, self-help books and other information for clients fit
into this process?
(3) Have you incorporated any technology into your sessions with
clients already? How did you do that, and what was the result?
(4) Are there any advantages to using technology, e.g. SHADE, as an
adjunct to your clinical practice? And what might the disadvantages
or concerns be? What are the main issues?
(5) What are some of the supervision and supports you think that you
might need to have in place to assist you in using technology in
your clinical practice?
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There was no prescription provided to clinicians as to
how, when or with whom the SHADE resource should
be used with their clients. However, clinicians suggested
that they would use it in the following ways:
(a) “Prescribe” modules for homework in between in-
person sessions;
(b) Complete individual modules during the session,
sitting side-by-side with clients;
(c) Provide the SHADE resource on DVD-Rom to
clients on the wait-list for the DACS;
(d) Use the handouts and worksheets from SHADE to
augment discussions about cognitive behavioural
skills conducted between clients and clinicians
during sessions;
(e) Use of the video and audio material to supplement
the relapse prevention group program conducted
by the DACS.
Current/ongoing clients
Following the provision of contact details to the research
team via their clinician, current and ongoing clients of
the DACS are contacted to discuss consent to participate
in the study. Once consent is established, clients
complete a baseline and 12-week follow-up assessment
delivered over the telephone by research assistants inde-
pendent from the DACS. Clients are reimbursed $20
AUD for each completed assessment.
Wait-list clients
New referral to the DACS, via the centralized intake ser-
vice, who have not been allocated to a clinician, will be
contacted by AH, SW or MB (clinicians of the DACS) to
discuss study participation and consent to release con-
tact details to the research team. Once these details have
been provided to the research team, wait-list clients con-
sent to complete a baseline and 12-week telephone as-
sessment in the same manner as current/ongoing
clients. Wait-list clients are reimbursed $20 AUD for
each completed assessment.
The SHADE treatment program
The SHADE treatment program has been described else-
where [16,20], and incorporates CBT and ME strategies
to encourage reductions in depression and AOD use.
The program is available in two formats: (i) a 10-session
program designed to be completed in a linear fashion,
once weekly for 10 weeks, with content pre-programmed
for each session; and (ii) a skill module program, where a
series of shorter modules are presented based on themes
related to depression and AOD use problems (e.g. coping
with cravings, taking charge of my thoughts, staying well)
arising from the 10-week program. Clients and/orclinicians may choose to focus on just one skill module
during a session, without having to complete the other
skills and strategies contained in the resource. Both ver-
sions of the SHADE program appear on the one DVD-
Rom from which the program operates. Text is pitched
at a reading age of 14 years, with a voiceover available to
read out all text contained in the resource. Video case
scenarios guide clients through a range of skills and strat-
egies, and a range of handouts and worksheets are also
available for clients/clinicians to print out and use during
a session or as a homework activity.
Assessments
All assessment instruments are widely used in mental
health and/or AOD treatment research and practice.
Clinicians
Clinicians will participate in a baseline focus group dis-
cussion designed to elicit their attitudes and concerns
about adopting innovation into their clinical practice in
general, and the SHADE treatment program in particu-
lar. Table 1 displays the structure of this focus group
discussion.
Subsequent to completing the focus group discussion,
clinicians complete two further self-report measures:
(1) Innovativeness Scale [21]: a 20-item measure using
a 7-point Likert-type scale assessing the likelihood
of an individual to adopt innovative strategies in
their work.
(2) Computer Opinion Survey [22]: a 26-item measure
using a 6-point Likert-type scale, developed as a
measure of the trait of computer anxiety rather
than the “state” of computer anxiety.
During the course of the study, clinicians complete a
session checklist at the conclusion of each session with a
client, which outlines the focus and content of the ses-
sion, including whether or not SHADE or other
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the authors to specifically suit the Central Coast DACS
and the range of counselling interventions applied by
the clinicians. At the conclusion of each counseling ses-
sion, clinicians complete a series of tick boxes to report
on: the session orientation (initial appointment, assess-
ment, scheduled appointment, non-scheduled client
contact, discharge/final session), the intervention ap-
plied, whether multimedia was used during the session
(if no, why not; if yes, specify the type, e.g. SHADE, and
the way in which it was used), whether debriefing was
held in relation to the multimedia used with the client,
and an approximation of the length of time multimedia
was discussed during the session. Please see Appendix A
for a copy of the session checklist.
At intake and discharge with a client, clinicians also
complete the therapist scale of the Agnew Relationship
Measure [23]. This scale asks clinicians to rate, on a 7-
point Likert scale, 28 items relating to the extent to
which they feel a bond, partnership, confidence, open-
ness, and client initiative are features of the therapeutic
relationship with their client.
Clients
Following the provision of consent, clients complete the
following set of assessment measures at baseline and 12-
weeks post-baseline via telephone with a trained re-
search clinician, who is independent of the Central
Coast DACS. The following questionnaires take between
30-45 minutes to complete:
(1) Demographics: information includes age, gender,
occupational and marital status, children,
educational experience, ethnicity and current
accommodation arrangements.
(2) Service Utilisation: includes current and previous
treatments, including self-reported hospitalisations,
attendance at clinics, rehabilitation programmes,
contact with community mental health teams,
psychologists, psychiatrists, other health
professionals, involvement in AOD detoxification
and counselling, methadone maintenance, 12-step
programmes, use of general practitioners, and use
of medication (including compliance).
(3) Opiate Treatment Index [24]: a quantity/frequency
index to estimate average daily use of 11 drug types
(alcohol, marijuana, heroin, other opiates,
amphetamines, cocaine, hallucinogens, barbiturates,
tranquilisers, inhalants and tobacco) in the month
prior to assessment.
(4) Treatment Motivation Questionnaire: is a 26 item
self-report measure, examining four components of
motivation including internal and external
motivation, help seeking and confidence intreatment. A 7-point Likert scale is used to
examine the level of motivation.
(5) Depression Anxiety Stress Scale 21-item version
[25]: a 21-item screening tool to for depression,
anxiety and stress in the previous 7 days. A 4-point
Likert-type scale is used to determine the extent to
which a symptom applied to the person.
(6) Global Assessment of Functioning [26]: a clinician-
rated assessment of current functioning.
(7) Self-compassion Scale [27]: is a 26-item measure
using a 5-point Likert-type scale assessing the
extent to which a person expresses self-compassion
towards themselves in difficult times.
(8) Agnew Relationship Measure – Client Version [23]:
this client-rated measure of therapeutic alliance is
similar in content and structure to the therapist-
rated version previously described.
We plan to report the cost of delivering the interven-
tion in real world settings and the cost impacts of the
outcomes achieved by calibration of selected instru-
ments used in the study (e.g. Quality of Life Scale, Glo-
bal Assessment of Functioning) with those achieved in
other costing studies.Sample size calculation
Clients
A 50% consent rate is estimated from the 250 eligible cli-
ents passing through the Central Coast DACS within the
study timeframe (N= 125). Previous research conducted
by the authors has achieved consent rates of 50% for par-
ticipants recruited from the general community [e.g. via
media advertisements, 16]. We obtained higher consent
rates (i.e. 82%) when previously recruiting directly from
DACS [16], however we have estimated our sample size
recruitment rates based on the lowest figure. Previous re-
search with the target population has resulted in an 80%
retention rate over a 15-week period [16], translating to a
final projected sample size of 100 retained participants at
the 15-week follow-up for the current study.Clinicians
All clinicians working with the Central Coast DACS are
invited to participate in the study, providing a maximum
of 19 clinician participants for the trial. Assuming clients
are distributed equally between the clinicians, each clin-
ician will see 13 clients during the study period (250/19).
Service data from the Central Coast DACS indicate the
average occasion of service for clients engaged with the
service is three sessions. Assuming a 50% compliance
rate with completion of session checklists by clinicians,
we estimate having a pool of 342 session checklists for
analysis.
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Clients
For the client sample, primary outcome measures are
changes in depression, alcohol and marijuana use be-
tween baseline and 12-week follow-up.
Previous research using the SHADE resource among
substance users [16] has resulted in effect size differences
of 0.42 between clients exposed to the SHADE resource
versus not on depression, alcohol and marijuana use. As-
suming similar effect size differences will apply to the
current study, we estimate that a sample size of 72 is
required at 15-week assessment to achieve adequate
power (power = 0.81) to detect differences of this order
using repeated measures analysis of variance with an alpha
level of 0.05 (calculated using G*Power, version 3.1.2). Pre-
dictors of alcohol use, marijuana use and depression at
15-weeks relevant to the current study (e.g. client rated
therapeutic alliance, internal and external motivation and
coerced vs non coerced clients, exposure to SHADE) will
be modelled using a linear regression analysis. This sample
size will also enable us to examine an effect size of 0.15 for
a linear multiple regression for these outcome variables,
with up to 6 predictors, an alpha level of 0.05 and a power
co-efficient of 0.80 (actual sample size required= 98).
Clinicians
Given the small sample size of clinicians associated with
the DACS, descriptive analyses only will be performed on
the clinician measures associated with innovation, com-
puter comfort and reported use of the SHADE resource.
Discussion
This will be the first real world dissemination trial of the
SHADE computerized resource; shown in previous re-
search to be efficacious in reducing depressive symp-
toms, alcohol and cannabis use among people reporting
these comorbid problems, under controlled research trial
conditions [16]. We will seek to establish the success
with which the SHADE resource is translatable to a
publicly-funded Drug and Alcohol Clinical Service. Ben-
nett and Glasgow [28] have recommended the RE-AIM
framework [29] as one that includes the critical factors in
disseminating technology-based interventions from the
research to the clinical setting. The RE-AIM factors are:
(a) Reach: report on the number and percent of
participants (eligible, consenting,
representativeness);
(b) Effectiveness: the change in key outcomes
associated with the intervention;
(c) Adoption: report on the number and
representativeness of staff in the clinical setting
who consent to participate in the dissemination
trial;(d) Implementation: how the program is delivered, and
whether there is consistency in delivery;
(e) Maintenance – individual: long-term effects on
individual outcomes; and
(f ) Maintenance – setting: sustainability of
implementation of the program following
completion of the trial.
The current study will cover the first four critical fac-
tors (Reach, Effectiveness, Adoption and Implementa-
tion), and over the longer term will seek approval to
monitor continued use of the SHADE resource in the
target Drug and Alcohol Clinical Service. In doing so, it
will address several key recommendations important in
achieving the goal of widespread dissemination of tech-
nology into clinical practice [28].
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